Objective To investigate the mechanism of bladder hydrodistension and combined with hyperbaric oxygen (HBO) in the treatment of interstitial cystitis (IC) and evaluate its therapeutic efficacy.Methods Twenty-three confirmed IC patients were treated with bladder hydrodistension plus HBO therapy.Results Two IC patients abandoned the therapy,due to intolerance to HBO pressure,the remaining 21 patients all completed the prescheduled therapy.As compared with those before therapy,statistical significance could be noticed in the scores of interstitial cystitis symptom index (ICSI),maximum urine volume,visual analogue scale (VAS),24-hour urination and quality of life (QOL),following 3 and 6 months of treatment respectively.Interestingly,the therapeutic efficacy after 3 months of treatment was more prominent(P ＜ 0.05) Conclusions Bladder hydrodistentioa combined with HBO therapy was a safe and effective treatment method for IC.However,its long term effect remained to be seen.

Objective To investigate the mechanism of bladder hydrodistension and combined with hyperbaric oxygen (HBO) in the treatment of interstitial cystitis (IC) and evaluate its therapeutic efficacy.Methods Twenty-three confirmed IC patients were treated with bladder hydrodistension plus HBO therapy.Results Two IC patients abandoned the therapy,due to intolerance to HBO pressure,the remaining 21 patients all completed the prescheduled therapy.As compared with those before therapy,statistical significance could be noticed in the scores of interstitial cystitis symptom index (ICSI),maximum urine volume,visual analogue scale (VAS),24-hour urination and quality of life (QOL),following 3 and 6 months of treatment respectively.Interestingly,the therapeutic efficacy after 3 months of treatment was more prominent(P ＜ 0.05) Conclusions Bladder hydrodistentioa combined with HBO therapy was a safe and effective treatment method for IC.However,its long term effect remained to be seen.

Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Lymphoma, Follicular ; drug therapy ; Rituximab

OBJECTIVEA prospective, multicenter and non-interventional prospective study was conducted to evaluate the clinical features of rituximab combined with chemotherapy (R-Chemo) as first-line treatment on newly diagnosed Chinese patients with diffuse large B-cell lymphoma (DLBCL).

METHODSThis was a single arm, prospective, observational multicenter and phase IV clinical trial for 279 patients, who were newly diagnosed as CD20-positive DLBCL from 24 medical centers in China 2011 and 2012, no special exclusion criteria were used. All patients received rituximab based R-Chemo regimes, such as R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) and other regimes as the first-line treatment. The treatment strategies were determined by physicians and patients without detailed description for treatment course, dose, interval time and examination. Clinical response and safety of all patients were investigated in 120 days after completion of last dose of rituximab.

RESULTSOf 279 patients, 258 with stage I-IV who received at least 1 cycle of rituximab treatment and completed at least one time of tumor assessment were enrolled into intention-to-treat analysis, including 148 male and 110 female. The median age of all patients was 57.2(12.8-88.4) years. ECOG performance statuses of 0 or 1 were observed in 91.1% of patients, international prognostic index levels in the low-risk and low-middle-risk groups in 76.4% of patients, the tumor diameters smaller than 7.5 cm in 69.0% of patients. All patients received 6 median cycles of R-Chemo treatment every 24.4 days. R-CHOP treatment was shown to improve the clinical response with overall response rates of 94.2%. Common adverse events included anemia, marrow failure, leukopenia, thrombocytopenia, digestive diseases, infection and liver toxicity. All adverse events are manageable.

CONCLUSIONNon-interventional clinical trial of R-Chemo remains the standard first-line treatment for newly diagnosed patients with DLBCL in real clinical practice, which is consistent with international treatment recommendations for DLBCL patients. R-Chemo can provide the clinical evidence and benefit as the first-line standard treatment for Chinese patients with DLBCL.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Child ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; Male ; Middle Aged ; Prospective Studies ; Rituximab ; Treatment Outcome